[Interactions between phenprocoumon (Marcumar) and drug-catabolizing, enzyme system-inducing pharmaceutic agents]. 1977

N Heni, and R Völger, and P Glogner

UI MeSH Term Description Entries
D008862 Microsomes, Liver Closed vesicles of fragmented endoplasmic reticulum created when liver cells or tissue are disrupted by homogenization. They may be smooth or rough. Liver Microsomes,Liver Microsome,Microsome, Liver
D010634 Phenobarbital A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. Phenemal,Phenobarbitone,Phenylbarbital,Gardenal,Hysteps,Luminal,Phenobarbital Sodium,Phenobarbital, Monosodium Salt,Phenylethylbarbituric Acid,Acid, Phenylethylbarbituric,Monosodium Salt Phenobarbital,Sodium, Phenobarbital
D010644 Phenprocoumon Coumarin derivative that acts as a long acting oral anticoagulant. Phenprocoumalol,Phenprocoumarol,Phenylpropylhydroxycumarinum,Falithrom,Liquamar,Marcoumar,Marcumar,Phenprogramma
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004790 Enzyme Induction An increase in the rate of synthesis of an enzyme due to the presence of an inducer which acts to derepress the gene responsible for enzyme synthesis. Induction, Enzyme
D005984 Glutethimide A hypnotic and sedative. Its use has been largely superseded by other drugs. Doriden,Noxiron
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012293 Rifampin A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) Rifampicin,Benemycin,Rifadin,Rimactan,Rimactane,Tubocin

Related Publications

N Heni, and R Völger, and P Glogner
May 1987, Deutsche medizinische Wochenschrift (1946),
N Heni, and R Völger, and P Glogner
January 1973, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
N Heni, and R Völger, and P Glogner
April 2001, Epilepsy & behavior : E&B,
N Heni, and R Völger, and P Glogner
February 1985, Fortschritte der Medizin,
N Heni, and R Völger, and P Glogner
May 2002, European journal of internal medicine,
N Heni, and R Völger, and P Glogner
May 2008, Current opinion in HIV and AIDS,
N Heni, and R Völger, and P Glogner
December 1975, International journal of clinical pharmacology and biopharmacy,
N Heni, and R Völger, and P Glogner
June 1976, International journal of clinical pharmacology and biopharmacy,
N Heni, and R Völger, and P Glogner
January 1972, Naunyn-Schmiedeberg's archives of pharmacology,
N Heni, and R Völger, and P Glogner
March 1996, Recenti progressi in medicina,
Copied contents to your clipboard!